(Q45396238)

14 December 2017

Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry (English)

1 reference

14 December 2017

1 reference

M Frogel

1

1 reference

14 December 2017

C Nerwen

2

1 reference

14 December 2017

A Cohen

3

1 reference

14 December 2017

P VanVeldhuisen

4

1 reference

14 December 2017

M Harrington

5

1 reference

14 December 2017

M Boron

6

1 reference

14 December 2017

Palivizumab Outcomes Registry Group

7

1 reference

14 December 2017

language of work or name

1 reference

27 March 2008

1 reference

14 December 2017

Journal of Perinatology

1 reference

14 December 2017

28

1 reference

14 December 2017

7

1 reference

14 December 2017

511-517

1 reference

https://scigraph.springernature.com/pub.10.1038/jp.2008.28

14 December 2017

0 references

cites work

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

Mortality associated with influenza and respiratory syncytial virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

The unresolved issue of risk factors for hospitalization of infants with respiratory syncytial virus infection born after 33-35 weeks gestation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FJP.2008.28

21 January 2018

https://api.crossref.org/works/10.1038%2FJP.2008.28

7 January 2021

Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: Results from the palivizumab outcomes registry

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

Risk factors for bronchiolitis-associated deaths among infants in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

Substantial variability in community respiratory syncytial virus season timing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

Defining the timing of respiratory syncytial virus (RSV) outbreaks: an epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

Respiratory syncytial viral infection in infants with congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

7 January 2021

Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

7 January 2021

Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry

1 reference

https://api.crossref.org/works/10.1038%2FJP.2008.28

7 January 2021

Identifiers

DOI

10.1038/JP.2008.28

1 reference

Dimensions Publication ID

14 December 2017

0 references

1 reference